NCT03972488 2026-01-21
NETTER-2
Advanced Accelerator Applications
Phase 3 Active not recruiting
Clinical Trials
23 trialsNCT05477576 2026-01-20
ACTION-1
RayzeBio, Inc.
Phase 3 Recruiting
NCT07262957 2025-12-22
PANENCA
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Phase 4 Recruiting
NCT02457156 2025-03-13
PANasta
University of Liverpool
Phase 3 Completed
NCT04871204 2024-10-31
OTIS
Karolinska University Hospital
Phase 2 Completed
NCT05701241 2024-06-14
SAUNA
University Hospital, Antwerp
Phase 4 Recruiting
NCT02381249 2023-11-27
The Effect of Satiety Gut Hormone Modulation on Appetitive Drive After Upper Gastrointestinal Surgery
St. James's Hospital, Ireland
Phase NA Completed
NCT02385617 2023-11-27
Food Intake and Gut Hormones in Patients Who Have Undergone Upper Gastrointestinal Surgery for Cancer
St. James's Hospital, Ireland
Phase NA Completed
NCT06080204 2023-10-18
Real-world Study on Adjuvant Octreotide Therapy in pNETs
Changhai Hospital
Phase NA Completed
NCT06085976 2023-10-17
Efficacy and Safety of Octreotide in Laparoscopic Hepatectomy Surgery: Effect on Blood Loss, Need for Vasoactive Drugs, Transfusion Requirements.
Clinica Universidad de Navarra, Universidad de Navarra
Phase 2 Unknown
NCT00003057 2023-06-18
Octreotide Compared With Loperamide Hydrochloride for Chemotherapy-Related Diarrhea in Patients With Colorectal Cancer
Eastern Cooperative Oncology Group
Phase 3 Completed
NCT03734627 2021-08-16
EndoGut
St. James's Hospital, Ireland
Completed
NCT02973204 2021-04-28
Circulating Tumor Cells and Tumor DNA in HCC and NET
University of Aarhus
Completed
NCT03812939 2019-01-23
Recurrence Rates of Type I Gastric Neuroendocrine Tumors Treated With Long-acting Somatostatin Analogs
Peking Union Medical College Hospital
Unknown
NCT00033605 2016-07-13
Octreotide in Preventing Diarrhea in Patients Who Are Undergoing Radiation Therapy to the Pelvis
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT00241020 2016-04-12
Evaluation of the Efficacy of Long-acting Release Octreotide in Patients With Advanced Hepatocellular Carcinoma
Novartis
Phase 3 Completed
NCT00075868 2015-11-17
Octreotide in Preventing or Reducing Diarrhea in Patients Receiving Chemoradiotherapy for Anal or Rectal Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
NCT00004895 2012-06-06
Octreotide as Palliative Therapy for Cancer-Related Bowel Obstruction That Cannot Be Removed by Surgery
Northwestern University
Phase 2 Completed
NCT00006269 2012-05-25
Octreotide in the Prevention of Diarrhea in Patients Receiving Irinotecan for Metastatic Colon Cancer
Novartis
Phase 3 Terminated
NCT00257426 2012-02-14
Octreotide in Treating Patients With Locally Advanced or Metastatic Liver Cancer
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT00250796 2010-01-07
Trial of Thalidomide, a- Interferon +/- Octreotide in Patients With Unresectable Hepatocellular Carcinoma
University of New Mexico
Phase 2 Completed
NCT00050635 2009-11-19
STOP Trial - Sandostatin LAR Depot Trial for the Optimum Prevention of Chemotherapy Induced Diarrhea
Novartis
Phase 4 Completed
NCT00386984 2006-10-12
Hector-Study to Evaluate the Efficacy of Octreotide in Patients With Inoperable Hepatocellular Carcinoma
University Hospital Freiburg
Phase 3 Completed